Free Industry Report

58% of CGT Facilities Cited by FDA Had Training Failures. Here's the Data.

12 FDA 483 inspections across cell and gene therapy manufacturing (2024–2025). Root cause breakdowns, CAPA models that worked, and a 12-week remediation timeline.

58%
Training-Linked
67%
Higher Citation Risk
89%
Using Generic Training

What's in the report

01

483 Language Pattern Analysis

The exact observation language FDA investigators are using across CGT visual inspection citations, so you can audit your program against real citation patterns.

02

Root Cause Breakdown

Why traditional pharma visual inspection training fails for cell therapy, viral vector, and gene editing products. Three specific failure modes with data.

03

Two CAPA Models That Worked

Real implementation timelines (45 and 60 days) from facilities that closed their 483s and passed follow-up inspections with zero repeat observations.

04

12-Week Remediation Timeline

Week-by-week action plan from gap assessment through validation, for facilities that need to move fast after a citation.

05

Proactive Audit Checklist

Training program design and documentation standards so you close gaps before FDA finds them.

Download the Executive Report

Subscribe below to receive a copy of the Executive Report - FDA 483 Training Gap Analysis

    We respect your privacy. Unsubscribe at any time.
    Based on 12 publicly documented FDA 483 inspections
    Sourced from FDA.gov, SEC filings, and industry press
    Prepared by Brian Drapeau, GxP Frame
    10+ years across Amgen, Novartis, BMS, Rocket, Lonza